ArticleBritish journal of clinical pharmacology2020

Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.

Jeroen V Koomen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.